Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. (PACB) Financial Performance & Income Statement Overview
Explore the financials of Pacific Biosciences of California, Inc. (PACB), including yearly and quarterly data on income, cash flow, and balance sheets.
Pacific Biosciences of California, Inc. (PACB) Income Statement & Financial Overview
Review Pacific Biosciences of California, Inc. PACB income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $37.15M | $39.22M | $39.97M | $36.01M |
| Cost of Revenue | $38.52M | $29.17M | $29.96M | $30.07M |
| Gross Profit | -$1.37M | $10.06M | $10.004M | $5.94M |
| Gross Profit Ratio | -$0.04 | $0.26 | $0.25 | $0.16 |
| R&D Expenses | $29.05M | $27.47M | $25.52M | $38.48M |
| SG&A Expenses | $40.17M | $41.64M | $43.75M | $45.88M |
| Operating Expenses | $401.23M | $68.61M | $69.26M | $68.30M |
| Total Costs & Expenses | $427.56M | $173.47M | $99.22M | $118.66M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $1.74M | $2.76M | $3.54M | $3.54M |
| Depreciation & Amortization | $0.00 | $10.95M | $16.10M | $14.29M |
| EBITDA | -$402.60M | $17.59M | -$41.09M | -$155.49M |
| EBITDA Ratio | -$10.84 | $0.45 | -$1.03 | -$4.32 |
| Operating Income | -$402.60M | -$153.03M | -$59.26M | -$175.85M |
| Operating Income Ratio | -$10.84 | -$3.90 | -$1.48 | -$4.88 |
| Other Income/Expenses (Net) | -$23.78M | $125.35M | -$1.47M | $2.53M |
| Income Before Tax | -$426.38M | $2.69M | -$60.73M | -$173.32M |
| Income Before Tax Ratio | -$11.48 | $0.07 | -$1.52 | -$4.81 |
| Income Tax Expense | -$302000.00 | $316000.00 | $0.00 | $0.00 |
| Net Income | -$426.07M | $2.37M | -$60.73M | -$173.32M |
| Net Income Ratio | -$11.47 | $0.06 | -$1.52 | -$4.81 |
| EPS | -$1.44 | $0.01 | -$0.22 | -$0.64 |
| Diluted EPS | -$1.44 | $0.008 | -$0.22 | -$0.64 |
| Weighted Avg Shares Outstanding | $296.86M | $283.00M | $272.92M | $272.38M |
| Weighted Avg Shares Outstanding (Diluted) | $296.86M | $306.89M | $272.92M | $272.38M |
Over the last four quarters, Pacific Biosciences of California, Inc. achieved steady financial progress, growing revenue from $36.01M in Q2 2024 to $37.15M in Q1 2025. Gross profit stayed firm with margins at -4% in Q1 2025 versus 16% in Q2 2024. Operating income totaled -$402.60M in Q1 2025, maintaining a -1084% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$402.60M. Net income dropped to -$426.07M, with EPS at -$1.44. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan